Monday, April 9, 2012
Tonix Pharmaceuticals Holding Corp., of New York, completed a trial of TNX-102 for fibromyalgia syndrome. The pharmacokinetic study suggested the drug could have similar benefits as low-dose cyclobenzaprine in fibromyalgia patients. That is the first of a number of formulations that the company will be testing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.